Can Spiolto Respimat (tiotropium/olodaterol) be used with an AeroChamber (valved holding chamber) without loss of efficacy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Spiolto Respimat Should NOT Be Used with an AeroChamber

Spiolto Respimat is a soft mist inhaler (SMI), not a pressurized metered-dose inhaler (pMDI), and therefore should not be used with an AeroChamber or any valved holding chamber (VHC). These devices are fundamentally incompatible, and attempting to use them together would likely result in significant loss of drug delivery and therapeutic efficacy.

Why This Combination Doesn't Work

Device Incompatibility

The Respimat inhaler generates a slow-moving aerosol cloud using mechanical energy from a spring mechanism, creating a unique soft mist that differs fundamentally from the propellant-driven spray of pMDIs 1. The spray duration is approximately 1.5 seconds, and the device is specifically engineered to deliver medication without requiring coordination between actuation and inhalation 1.

AeroChambers and other VHCs are designed exclusively for use with pMDIs - devices that use propellants to generate aerosol 2, 3, 4. The physical connection, aerosol characteristics, and delivery mechanisms are completely different between these device types.

Evidence from Related Research

While there is one study examining tiotropium Respimat with AeroChamber in young children (1-5 years old) 5, this was a specialized investigation for a specific vulnerable population where alternative delivery methods are limited. The study required extensive in vitro characterization and demonstrated that approximately one-third of the labeled dose was delivered - a significant reduction 5. This is not standard practice and should not be extrapolated to adult COPD patients who can use the Respimat device as intended.

Another study examined tiotropium Respimat with and without a spacer in COPD patients 6, but this appears to be an off-label investigation rather than manufacturer-recommended or guideline-supported practice.

Proper Use of Spiolto Respimat

The FDA-approved labeling for Spiolto Respimat specifies that each dose delivers 5 mcg tiotropium and 5 mcg olodaterol from the mouthpiece when used with the Respimat inhaler device 1. The device is designed for direct inhalation, with the patient breathing in slowly and deeply during the 1.5-second spray duration 1.

The Respimat inhaler already addresses many of the coordination challenges that VHCs solve for pMDIs:

  • Slow-moving aerosol cloud (easier to inhale)
  • Longer spray duration (1.5 seconds)
  • No cold Freon effect
  • Lower oropharyngeal deposition compared to pMDIs

Clinical Implications

If a patient cannot properly use the Respimat device due to:

  • Severe cognitive impairment
  • Inability to coordinate inhalation
  • Physical limitations affecting hand-breath coordination

The appropriate solution is NOT to add a VHC, but rather to:

  1. Consider switching to a different delivery system (dry powder inhaler if inspiratory flow adequate, or nebulized alternatives)
  2. Provide intensive patient education and technique training
  3. Reassess whether the patient is an appropriate candidate for this specific device

The guidelines support using alternative delivery devices when patients cannot effectively use their prescribed inhaler 7, but this means switching devices entirely, not attempting to modify an incompatible system.

Bottom Line

Do not use Spiolto Respimat with an AeroChamber. These devices are not designed to work together, and such use would be off-label with unpredictable drug delivery. If a patient cannot use the Respimat properly, discuss alternative bronchodilator delivery systems with appropriate device characteristics for that patient's capabilities.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.